SEARCH

SEARCH BY CITATION

References

  • 1
    Chang-Claude J. BRCA1/2 and the prevention of breast cancer. In: KhouryMJ, LittleJ, BurkeW, editors. Human genome epidemiology. Oxford: Oxford University Press; 2004. 45174.
  • 2
    American cancer society: cancer facts and figures 2005. Atlanta, GA: American Cancer Society, 2004 [consulted on May 6, 2006]. Available from: http://seer.cancer.gov/csr/1975_2002/results_single/sect_01_table.01.pdf.
  • 3
    Tranchemontagne J, Boothroyd L, Blancquaert I. Contribution of BRCA 1/2 mutation testing to risk assessment for susceptibility to breast and ovarian cancer. Montreal: AETMIS, 2006. Summary Report.
  • 4
    Wolfberg AJ. Genes on the web-direct-to-consumer marketing of genetic testing. N Engl J Med 2006; 355: 5435.
  • 5
    National Health Service. Critical Appraisal Skills Programme [Internet]. UK: CASP, 2004. [consulted on July 6, 2005]. Available from: http://www.phru.nhs.uk/casp/appraisa.htm.
  • 6
    Rochon PA, Gurwitz JH, Sykora K, Mamdani M, Streiner DL, Garfinkel S, Normand SL, Anderson GM. Reader's guide to critical appraisal of cohort studies. I. Role and design. BMJ 2005; 330: 8957.
  • 7
    Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC, Rochon PA, Anderson GM. Reader's guide to critical appraisal of cohort studies. II. Assessing potential for confounding. BMJ 2005; 330: 9602.
  • 8
    Normand SL, Sykora K, Li P, Mamdani M, Rochon PA, Anderson GM. Reader's guide to critical appraisal of cohort studies. III. Analytical strategies to reduce confounding. BMJ 2005; 330: 10213.
  • 9
    Lostumbo L, Carbine N, Wallace J, Ezzo J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2004; 18: CD002748. DOI: 10.1002/14651858.CD002748.pub2.
  • 10
    Calderon-Margalit R, Paltiel O. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature. Int J Cancer 2004; 112: 35764.
  • 11
    Meijers-Heijboer H, van Geel B, van Putten WLJ, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers M, Bartels C, Verhoog L, van den Ouweland A, Niermeijer M, Brekelmans C, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 15964.
  • 12
    Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22: 105562.
  • 13
    van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, Van Asperen CJ, Rutgers EJT, Van't Veer LJ, Tollenaar RA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005; 93: 28792.
  • 14
    Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999; 91: 14759.
  • 15
    Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL, et al. Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346: 161622.
  • 16
    Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Huddis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, et al. Risk reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346: 160915.
  • 17
    Moller P, Borg A, Evans DG, Haites N, Reis MM, Vasen H, Anderson E, Steel CM, Apold J, Goudie D, Howell A, Lalloo F, et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 2002; 101: 5559.
  • 18
    Laframboise S, Nedelcu R, Murphy J, Cole DE, Rosen B. Use of CA-125 and ultrasound in high-risk women. Int J Gynecol Cancer 2002; 12: 8691.
  • 19
    Meeuwissen PA, Seynaeve C, Brekelmans CT, Meijers-Heijboer HJ, Klijn JG, Burger CW. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 2005; 97: 47682.
  • 20
    Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, van't Veer LJ. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 2004; 90: 14927.
  • 21
    Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Neuhausen SL. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001; 357: 146770.
  • 22
    Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen S, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H. Tamoxifen and risk of contralateral breast cancer in BRCA 1 and BRCA 2 mutation carriers: a case-control study. Lancet 2000; 356: 187681.
  • 23
    Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, Provencher D, Heimdal K, Moller P, Robson M, Offit K, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002; 94: 17739.
  • 24
    Heimdal K, Skovlund E, Moller P. Oral contraceptives and risk of familial breast cancer. Cancer Detect Prev 2002; 26: 237.
  • 25
    Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Ponder BA. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 1998; 339: 4248.
  • 26
    Whittemore AS, Balise RR, Pharoah PD, Dicioccio RA, Oakley- Girvan I, Ramus SJ, Daly M, Usinowicz MB, Garlinghouse-Jones K, Ponder BA, Buys S, Senie R, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 2004; 91: 19115.
  • 27
    Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006; 118: 22814.
  • 28
    Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006; 296: 18592.
  • 29
    Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, Daly MB, Eeles R, Matloff E, Tomlinson GE, Van't Veer L, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006; 7: 2239.
  • 30
    Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication Bias in clinical research. Lancet 1991; 337: 86772.
  • 31
    Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 7784.
  • 32
    Friedenson B. BRCA1 and BRCA 2 pathway and the risk of cancers other than breast or ovarian. MedGenMed 2005; 7: 60.
  • 33
    Gabriel SE, Woods JE, O'Fallon WM, Beard CM, Kurland LT, Melton LJ. Complications leading to surgery after breast implantation. N Engl J Med 1997; 336: 67782.
  • 34
    Mirhashemi R, Harlow BL, Ginsburg ES, Signorello LB, Berkowitz R, Feldman S. Predicting risk of complications with gynecologic laparoscopic surgery. Obst Gynecol 1998; 92: 32731.
  • 35
    Makinen J, Johansson J, Tomas C, Tomas E, Heinonen PK, Laatikainen T, Kauko M, Heikkinen AM, Sjoberg J. Morbidity of 10 110 hysterectomies by type of approach. Hum Reprod 2001; 16: 14738.
  • 36
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal result from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 32133.
  • 37
    Tiller K, Meiser B, Butow P, Clifton M, Thewes B, Friedlander M, Tucker K. Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study. Gynecol Oncol 2002; 86: 2129.
  • 38
    Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 2001; 10: 23141.
  • 39
    Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 111730.
  • 40
    McGahan L, Kakuma R, Ho C, Bassett K, Noorani HZ, Joyce J, Allanson J, Taylor S. BRCA1 and BRCA2 predictive genetic testing for breast and ovarian cancers: a systematic review of clinical evidence, Tech. Rep. No. 66. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2006.
  • 41
    Nelson HD, Huffman LH, Fu R, Harris EL; U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005; 143: 36279.